Last reviewed · How we verify
Cymbalta®
Cymbalta®, marketed by Eurofarma Laboratorios S.A., is a well-established drug in the pharmaceutical market with a key composition patent expiring in 2028. Its primary strength lies in its strong market presence and established revenue stream. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Cymbalta® |
|---|---|
| Also known as | Reference drug, Duloxetine |
| Sponsor | Eurofarma Laboratorios S.A. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy (PHASE3)
- Focal Microvibration and Chronic Lumbosacral Radicular Pain (NA)
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (PHASE3)
- Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] (PHASE1)
- Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life (PHASE4)
- A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta (PHASE4)
- A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |